ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 04/12/24

2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...

2024-04-11 07:33:18 ET More on Zentalis Pharmaceuticals Zentalis Pharmaceuticals: Azenosertib Continues To Impress Zentalis: Leading WEE1 Developer After AstraZeneca's Exit Read the full article on Seeking Alpha For further details see: Zentalis Pharmaceu...

NEW YORK and SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, wi...

2024-03-28 16:52:13 ET Gainers: Semtech Corporation ( SMTC ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Sagimet Biosciences  ( SGMT ) +5% . Photronics ( PLAB ) +5% . James River Group Holdings ( JRVR ) +4% . Losers...

2024-03-27 00:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 16:46:57 ET Gainers: ESGEN Acquisition  ( ESAC ) +40% . LifeMD ( LFMD ) +7% . Mission Produce ( AVO ) +4% . Flex  ( FLEX ) +4% . Purple Innovation ( PRPL ) +3% . Losers: Power & Digital Infrastruc...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today ann...

Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024 Strengthened management team with appointments of Diana Hausman, M.D., ...

NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today ann...